 By David Bautz, PhD NASDAQ:BCLI READ THE FULL BCLI RESEARCH REPORT Business Update KOL Event for Alzheimers Program On July 8, 2020, BrainStorm Cell Therapeutics, Inc. NASDAQ:BCLI conducted a Key Opinion Leader KOL webinar to discuss the companys upcoming Phase 2a clinical trial of NurOwn in patients with Alzheimers Disease AD. The event included presentations by two of the lead 